CoChat

Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease

Cho, Jin Ah, Chinnapen, Daniel J.F. · 2018 · Journal of Microbiology

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Mucosal surfaces that line our gastrointestinal tract are continuously exposed to trillions of bacteria that form a symbiotic relationship and impact host health and disease. It is only beginning to be understood that the cross-talk between the host and microbiome involve dynamic changes in commensal bacterial population, secretion, and absorption of metabolites between the host and microbiome. As emerging evidence implicates dysbiosis of gut microbiota in the pathology and progression of various diseases such as inflammatory bowel disease, obesity, and allergy, conventional treatments that either overlook the microbiome in the mechanism of action, or eliminate vast populations of microbes via wide-spectrum antibiotics need to be reconsidered. It is also becoming clear the microbiome can influence the body's response to therapeutic treatments for cancers. As such, targeting the microbiome as treatment has garnered much recent attention and excitement from numerous research labs and biotechnology companies. Treatments range from fecal microbial transplantation to precision-guided molecular approaches. Here, we survey recent progress in the development of innovative therapeutics that target the microbiome to treat disease, and highlight key findings in the interplay between host microbes and therapy.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12275-018-8037-z

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Talbot, A.M. 2017. Vedanta biosciences announces initiation of phase 1a/1b trial for new drug class of rationally-defined bacterial consortia derived from the human microbiome. Business Wire. PureTech Health. Available at https://www.businesswire. com/news/home/20171206006422/en/Vedanta-Biosciences-An nounces-Initiation-Phase-1a1b-Trial (accessed December 07, 2017).

Cited by

See all 19

Metadata

Authors
Cho, J. A., & Chinnapen, D. J. F.
Affiliations
  • Chungnam National University (KR)
  • Boston Children's Hospital (US)
Corresponding author
Chinnapen, Daniel J.F.
Venue
Journal of Microbiology
Published
2018-02-28
Volume
56
Issue
3
Pages
183-188
ISSN
  • 1225-8873 (ISSN-L)
  • 1976-3794
OpenAlex
W2794371886
Cited by
19
References
50
Citations by year
2026: 1 · 2025: 2 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 2
FWCI
0.29
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • The Journal of Microbiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Chungnam National University
  • National Research Foundation of Korea
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
gut microbiota, microbiota-based therapy, dysbiosis, host-microbe interactions, commensal bacteria, metabolite exchange, inflammatory bowel disease, obesity, allergy, cancer immunotherapy, fecal microbiota transplantation, antibiotics
MeSH terms
Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Anti-Bacterial Agents, Gastrointestinal Diseases, Humans, Hypersensitivity, Neoplasms, Obesity, Symbiosis, Inflammatory Bowel Diseases, Probiotics, Gastrointestinal Tract, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease. https://app.cochat.ai/papers/10.1007/s12275-018-8037-z
The paper
Cho, J. A., & Chinnapen, D. J. F. (2018). Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease. Journal of Microbiology. https://doi.org/10.1007/s12275-018-8037-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.